Tech Company Financing Transactions
PharmAkea Therapeutics Funding Round
Bay City Capital and Celgene joined a $45 million Series A venture round for PharmAkea Therapeutics. The financing round was announced on 10/8/2013.
Transaction Overview
Company Name
Announced On
10/8/2013
Transaction Type
Venture Equity
Amount
$45,000,000
Round
Series A
Investors
Bay City Capital (Carl Goldfischer)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3030 Bunker Hill St. 300
San Diego, CA 92109
USA
San Diego, CA 92109
USA
Phone
Undisclosed
Website
Email Address
Overview
PharmAkea is a biopharmaceutical company based in San Diego, CA. The company is developing high-quality, small molecule drug candidates against protein targets involved in fibroproliferative diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robert Williamson
Chief Operating Officer
Kevin Holme
VP - Finance
Vanessa Jacoby
Browse more venture capital transactions:
Prev: 10/8/2013: Swirl Networks venture capital transaction
Next: 10/8/2013: Versartis venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs